Increased Tissue Pressure Induces Demyelinated Lesions and Necroses in the Brain
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Headache in Multiple Sclerosis from a Different Perspective: a Prospective Study
Volume 9 • Number 1 • March 2018 JOURNAL OF CLINICAL AND RESEARCHORIGINAL ARTICLEARTICLE EXPERIMENTAL INVESTIGATIONS Headache in Multiple Sclerosis from A Different Perspective: A Prospective Study Gökhan Özer¹, Ufuk Ergün², Levent Ertuğrul İnan³ 1 Sanko University Faculty of Medicine, Department of Neurology, Gaziantep, ABSTRACT Turkey Objective: It is known that patients with multiple sclerosis have a high incidence of headache. 2 Kırıkkale University School of Medicine, Kırıkkale, Turkey Although there is increasing evidence to suggest that periaqueductal gray matter (PAG) plays 3 Bozok University School of Medicine, a role in the pathophysiology of migraine headache, it is not known whether the type of Yozgat, Turkey headache may be a predictor of a MS relapse. Patients and Methods: The study enrolled 100 patients (68 females, 32 males) with clinically confirmed MS diagnosis established by McDonald diagnostic criteria. The type and duration of MS, MRI localization of lesions and cognitive status were recorded for all patients. Patients were questioned whether they experience headache during MS attacks. Results: Sixty-eight percent of the patients had headache and 32% of the patients were free of headache. Of the patients with headache, 16% had tension –type headache (TTH), 14% had migraine, 11% had primary stabbing headache (PSH), 8% had TTH+ migraine, 6% had PSH+ migraine, 6% had medication overuse headache , 2% had medication overuse headache + E-mail: [email protected] migraine, 2% had paroxysmal hemicrania, 1% had cervicogenic headache, 1% had chronic TTH, E-mail: [email protected] and 1% had unclassified headache. There was a statistically significant relationship between the E-mail: [email protected] presence of headache and MS relapse (p<0.001). -
Multiple Sclerosis Accepted: 15 May 2016 Receiving Tysabri
Iranian Journal Letter to Editor of Neurology Iran J Neurol 2016; 15(3): 175-176 Bacterial meningitis in a patient Received: 10 Mar 2016 with multiple sclerosis Accepted: 15 May 2016 receiving Tysabri Abdorreza Naser Moghadasi1, Soroor Advani2, Shiva Rahimi2 1 Multiple Sclerosis Research Center, Neuroscience Institute, Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran 2 Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran Keywords lesions (Figure 1-A) with no evidence of PML or Bacterial Meningitis; Multiple Sclerosis; Tysabri HSE encephalitis. Meningeal enhancement was seen after the injection of the contrast medium (Figure 1-B). The most important adverse effect of natalizumab is progressive multifocal leukoencephalopathy (PML).1 Apart from PML, there are reports of other cerebral infections including herpes simplex encephalitis (HSE)2,3 and cryptococcal meningitis4 in the literature. The patient was a 29-year-old woman, a known case of multiple sclerosis (MS) for at least 5 years. She was treated using natalizumab since 6 month before. She was under treatment with prednisolone 1 g daily for 5 days for optic neuritis, which was 2 weeks before the onset of symptoms of meningitis. Approximately three days before visiting the neurologist, a continuous headache in the left temporal lobe was developed. Figure 1. Periventricular lesions confirming the The patient was febrile at that time as well. diagnosis of multiple sclerosis (MS) in the FLAIR MRI Besides, two days before this, she had started view (A). Meningeal enhancement was seen after ciprofloxacin for treatment of a urinary gadolinium injection (B) tract infection. -
Serial Magnetic Resonance Imaging Changes of Pseudotumor Lesions In
Yan et al. BMC Neurol (2021) 21:219 https://doi.org/10.1186/s12883-021-02250-4 CASE REPORT Open Access Serial magnetic resonance imaging changes of pseudotumor lesions in retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations: a case report Yuying Yan1, Shuai Jiang1, Ruilin Wang2, Xiang Wang3, Peng Li3* and Bo Wu1* Abstract Background: Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) is an adult-onset rare monogenic microvasculopathy. Its typical neuroimaging features are punctate white matter lesions or pseudotumor alterations. RVCL-S is often under-recognized and misdiagnosed because of its rarity and similar imaging manifestations to multiple sclerosis or brain malignant mass. Case presentation: Here we report a case of a 36-year-old Chinese man who developed multiple tumefactive brain lesions spanning over two years leading to motor aphasia, cognitive decline, and limb weakness. He also presented with slight vision loss, and fundus fuorescein angiography indicated retinal vasculopathy. He underwent brain biopsies twice and showed no evidence of malignancy. Given the family history that his father died of a brain mass of unclear etiology, RVCL-S was suspected, and genetic analysis confrmed the diagnosis with a heterozygous insertion mutation in the three-prime repair exonuclease 1 gene. He was given courses of corticosteroids and cyclophospha- mide but received little response. Conclusions: The present case is one of the few published reports of RVCL-S with two-year detailed imaging data. Serial magnetic resonance images showed the progression pattern of the lesions. Our experience emphasizes that a better understanding of RVCL-S and considering it as a diferential diagnosis in patients with tumefactive brain lesions may help avoid unnecessary invasive examinations and make an earlier diagnosis. -
Radiologically Isolated Syndrome: a Review for Neuroradiologists
REVIEW ARTICLE Radiologically Isolated Syndrome: A Review for Neuroradiologists M. Hosseiny, S.D. Newsome, and D.M. Yousem ABSTRACT SUMMARY: Radiologically isolated syndrome refers to an entity in which white matter lesions fulfilling the criteria for multiple sclerosis occur in individuals without a history of a clinical demyelinating attack or alternative etiology. Since its introduction in 2009, the diagnostic criteria of radiologically isolated syndrome and its clinical relevance have been widely debated by neu- rologists and radiologists. The aim of the present study was to review the following: 1) historical evolution of radiologically iso- lated syndrome criteria, 2) clinical and imaging findings in adults and children with radiologically isolated syndrome, 3) imaging features of patients with radiologically isolated syndrome at high risk for conversion to MS, and 4) challenges and controversies for work-up, management, and therapeutic interventions of patients with radiologically isolated syndrome. ABBREVIATIONS: CIS ¼ clinically isolated syndrome; DIS ¼ dissemination in space; DIT ¼ dissemination in time; MAGNIMS ¼ Magnetic Resonance Imaging in MS; RIS ¼ radiologically isolated syndrome; RRMS ¼ relapsing-remitting multiple sclerosis; CADASIL ¼ cerebral autosomal dominant arteriopathy with sub- cortical infarcts and leukoencephalopathy; ADEM ¼ acute disseminated encephalomyelitis adiologically isolated syndrome (RIS) refers to an entity in patients are being evaluated for headache, trauma, or nonspecific Rwhich brain or spine MR -
Demyelination: What Is It and Why Does It Happen?
Demyelination: What Is It and Why Does It Happen? • Causes • Symptoms • Types • MS and Demyelination • Treatment and Diagnosis • Vaccines • Takeaway What is demyelination? Nerves send and receive messages from every part of your body and process them in your brain. Nerves allow you to speak, see, feel, and think. Many nerves are coated in myelin. Myelin is an insulating material. When it’s worn away or damaged, nerves can deteriorate, causing problems in the brain and throughout the body. Damage to myelin around nerves is called demyelination. Nerves Nerves are made up of neurons. Neurons are composed of a cell body, dendrites, and an axon. The axon sends messages from one neuron to the next. The axon also connects neurons to other cells, such as muscle cells. Some axons are extremely short. Others are 3 feet long. Some axons are covered in myelin. Myelin protects the axons and helps carry axon messages as quickly as possible. Myelin Myelin is made of membrane layers that cover an axon. This is similar to the idea of an electrical wire with coating to protect the metal underneath. Myelin allows a nerve signal to travel faster. In unmyelinated neurons, a signal can travel along the nerves at about 1 meter per second. In a myelinated neuron, the signal can travel 100 meters per second. Certain diseases can damage myelin. Demyelination slows down messages sent along axons and causes the axon to deteriorate. Depending upon the location of the damage, axon loss can cause problems with feeling, moving, seeing, hearing, and thinking clearly. CAUSES Causes of demyelination Inflammation is the most common cause of myelin damage. -
Acute Disseminated Encephalomyelitis Or Multiple Sclerosis: Can the Initial Presentation Help in Establishing a Correct Diagnosi
636 REVIEW Acute disseminated encephalomyelitis or multiple sclerosis: can the initial presentation help in establishing a correct Arch Dis Child: first published as on 20 May 2005. Downloaded from diagnosis? R C Dale, J A Branson ............................................................................................................................... Arch Dis Child 2005;90:636–639. doi: 10.1136/adc.2004.062935 The differential diagnosis of CNS white matter disease is and MS cases must manifest disseminated disease of the CNS (more than one clinical or broad, and can be divided into vascular, metabolic, radiological site). Diseases isolated to specific infective, or inflammatory aetiologies. Isolated areas of the CNS (isolated optic neuritis, trans- inflammatory disorders of the CNS are often associated verse myelitis, and brain stem dysfunction) are considered distinct from both ADEM and MS with demyelination, and the two terms (inflammatory and (clinically and prognostically), and will not be demyelinating) are often used in conjunction. When the discussed in this review.89 disease is monophasic, the term acute disseminated 1 DEMOGRAPHICS encephalomyelitis (ADEM) is used. ADEM typically occurs Monophasic ADEM is more common in children, as a post-infectious phenomenon, and by definition, must whereas MS is more common in adults. Between be an isolated (monophasic) episode. If a relapse occurs 2.7% and 4.4% of MS presentations occur in children less than 16 years of age.8 Mikaeloff et al shortly after the ADEM presentation in association with a showed a mean age of 7.1 years and 12.0 years in further infection or steroid withdrawal, the term MDEM paediatric ADEM and MS patients respectively.8 (multiphasic disseminated encephalomyelitis) is used. -
A Diffusion Tensor Magnetic Resonance Imaging Study of Brain Tissue from Patients with Migraine M a Rocca, B Colombo, M Inglese, M Codella, G Comi, M Filippi
501 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.74.4.501 on 1 April 2003. Downloaded from SHORT REPORT A diffusion tensor magnetic resonance imaging study of brain tissue from patients with migraine M A Rocca, B Colombo, M Inglese, M Codella, G Comi, M Filippi ............................................................................................................................. J Neurol Neurosurg Psychiatry 2003;74:501–503 PATIENTS AND METHODS Objective: To measure in vivo, using diffusion tensor mag- We studied 34 patients (31 women and three men; mean age netic resonance imaging (DT-MRI) the extent of pathologi- 35.2 years, range 18–55 years; mean duration of the disease cal damage of normal appearing brain tissue (NABT) from 13.6 years, range 1–40 years; mean number of episodes per patients with migraine. year 44.6, range 12–70) with migraine.10 All possible alterna- Methods: Dual echo and DT-MRI scans of the brain were tive diagnoses were carefully excluded.10 There were 28 acquired from 34 patients with migraine and 17 sex and patients affected by “migraine without aura” and six patients age matched healthy volunteers. Mean diffusivity (MD) affected by “migraine with aura”.10 Patients with hyper- and fractional anisotropy (FA) histograms of the NABT tension, hypercholesteraemia, diabetes mellitus, vascular/ were obtained from all subjects and the histograms’ peak heart diseases, and other major systemic and neurological heights and average NABT MD and FA measured. When conditions were excluded. At the time of the MRI assessment, present, average MD and FA values of T2 visible lesions 11 patients were treated with prophylactic drugs. Seventeen were also measured. -
Updated Criteria for Diagnosing Multiple Sclerosis
r e v i e w a r t i c l e Updated criteria for diagnosing Multiple Sclerosis or in the case of progressive MS, a slow or step- Key take home messages wise progression of disability over a period of • The diagnostic criteria for MS have at least six months been recently updated • and objective clinical evidence of lesions in • These criteria should only be applied two or more distinct sites in the white matter to populations in whom MS is of the central nervous system common and patients who present • with no more satisfactory explanation. Peter Brex with typical symptoms for which no The Schumacher criteria were purely clinical, MB BS, MD, FRCP is a Consultant Neurologist at King’s College Hospital better explanation can be found although investigations were encouraged (blood, NHS Foundation Trust. He trained in • All patients with suspected MS should urine, chest X-ray, CSF analysis) to exclude London and was appointed to his current have an MRI brain scan; spinal cord alternative conditions. role in 2005. He specialises in multiple imaging is not mandatory Over the next few years modifications to the sclerosis, with a particular interest in early 2,3 prognostic markers and the management • Unmatched oligoclonal bands in the Schumacher criteria were published but in 1983 of MS during pregnancy. CSF can be used as a substitute for the Schumacher criteria were replaced by criteria demonstrating dissemination in time, developed by a committee chaired by Charles allowing an earlier diagnosis than was Poser (1923 – 2010).4 The Poser criteria incorpor- previously possible ated laboratory and clinical tests developed in the previous decade to support the diagnosis with ‘paraclinical evidence’ of lesions. -
Neurodegeneration and Neuroprotection in Multiple Sclerosis and Other Neurodegenerative Diseases ⁎ Suhayl Dhib-Jalbut , Douglas L
Journal of Neuroimmunology 176 (2006) 198–215 www.elsevier.com/locate/jneuroim Conference report Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases ⁎ Suhayl Dhib-Jalbut , Douglas L. Arnold, Don W. Cleveland, Mark Fisher, Robert M. Friedlander, M. Maral Mouradian, Serge Przedborski, Bruce D. Trapp, Tony Wyss-Coray, V. Wee Yong UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, United States McGill University, Montreal, Quebec, Canada UCSD, San Diego, CA, United States University of Massachusetts, Worcester, MA, United States Harvard Medical School, Boston, MA, United States Columbia University, New York, NY, United States The Cleveland Clinic, Cleveland, OH, United States Stanford University, Paolo Alto, CA, United States University of Calgary, Calgary, Alberta, Canada Received 3 March 2006; accepted 6 March 2006 Abstract Multiple sclerosis is considered a disease of myelin destruction; Parkinson's disease (PD), one of dopaminergic neuron depletion; ALS, a disease of motor neuron death; and Alzheimer's, a disease of plaques and tangles. Although these disorders differ in important ways, they also have common pathogenic features, including inflammation, genetic mutations, inappropriate protein aggregates (e.g., Lewy bodies, amyloid plaques), and biochemical defects leading to apoptosis, such as oxidative stress and mitochondrial dysfunction. In most disorders, it remains uncertain whether inflammation and protein aggregation are neurotoxic or neuroprotective. Elucidating the mechanisms -
Multiple Sclerosis (MS) What Do I Need to Know?
I’m Caring for a Veteran with Multiple Sclerosis (MS) What Do I Need to Know? Physical and Mental Changes to Expect Symptoms of multiple sclerosis (MS) can vary greatly from Veteran to Veteran and from time to time in the same person. For instance, one person with MS may experience abnormal fatigue and another person may have severe vision problems. While one person with MS may have loss of balance, muscle coordination or tremors — making walking and everyday tasks difficult to perform — another person may have slurred speech and memory issues. Some Facts These problems may be permanent or may come and go. Depression is frequently experienced by MS patients and can have a significant What is Multiple Sclerosis? impact on quality of life. Multiple sclerosis (MS) is an Physical changes may include: visual disturbances; difficulty in unpredictable, often disabling controlling strength and movements; impaired coordination and balance; disease of the central nervous numbness; tingling; sensitivity to heat and cold; bladder control problems; system that interrupts the flow of urinary tract infections; mild to severe fatigue and weakness information within the brain and between the brain and the body Mental changes may include: problems with memory and concentration and stops people from moving. Emotional changes may include: mood swings, ranging from depression Symptoms range from numbness to euphoria and tingling to blindness and paralysis. The progress, severity, and specific symptoms of MS in any one What Does This Mean for Me? person cannot yet be predicted. MS affects not only the Veterans with the illness, but also family members Treatment may include: and friends. -
(Pre-Allison & Millar) Ipsen Criteria: 1939-48, Boston, MA
Early criteria (pre-Allison & Millar) Ipsen criteria: 1939-48, Boston, MA USA1 - Probable MS o Those cases with records presenting convincing evidence - Possible MS o Those cases whose evidence was more doubtful. Ipsen acknowledges these allocations are fairly arbitrary but also notes that absolutely certainty of diagnosis is impossible except by autopsy, a limitation we are similarly affected by even today. Westlund & Kurland: 1951, Winnipeg, MT Canada & New Orleans, LA USA2 Diagnostic groupings as follows, with no explicit requirements for each, rather deferring to the discretion of the examining neurologist: - Certain MS - Probable MS - Possible MS o In this class, the changes for and against MS were considered approximately even - Doubtful, unlikely or definitely-not MS2 Sutherland criteria: 1954, Northern Scotland3 - Probable MS o This category for patients in whom the history, the results of clinical examination and, where available, hospital investigations, indicated that the diagnosis of MS was beyond reasonable doubt. - Possible MS o Patients in whom a diagnosis of MS appears justifiable but in which the diagnosis could not be established beyond reasonable doubt; o This group also included patients who did not wish to be examined or could not be seen – review of hospital records for these patients suggested a diagnosis of MS - Rejected cases o Patients found to be suffering from a disease other than MS Allison & Millar Criteria and variants Allison & Millar criteria: 1954, Northern Ireland4 - Early disseminated sclerosis: 1) this category for patients with little in the way of symptomatic presentation but with a recent history consistent with disease onset, i.e. optic neuritis, ophthalmoplegia (double vision), vertigo, sensory problems like pins & needles or numbness, or motor problems like weakness. -
Pediatric MS and Other Demyelinating Disorders in Childhood Current Understanding, Diagnosis and Management 24
Pediatric MS and other demyelinating disorders in childhood Current understanding, diagnosis and management 24 Contents Pediatric MS from the perspective of both the 4 child and the family Biological reasons why children develop MS 4 Genetic and environmental risk factors for 5 pediatric MS Clinical features and outcome 6 Cognition and mood 6 MRI features 7 Conventional first-line treatment and general 7 management Escalation and emerging treatments 9 Defining MS in childhood and differentiating it 9 from mimics Acute disseminated encephalomyelitis (ADEM) 10 Acute transverse myelitis (ATM) 10 Optic neuritis 11 Neuromyelitis optica (NMO) 11 Acquired demyelinating syndrome (ADS) 12 References and further reading 13 Contributors The articles summarised in this publication are taken from a 2016 Neurology journal supplement, written by the International Pediatric MS Study Group. We gratefully acknowledge the editorial contribution of Dr Rosalind Kalb. Funders Associazione Italiana Sclerosi Multipla, Deutsche Multiple Sklerose Gesellschaft Bundesverband, MS Cure Fund, National MS Society (USA), Schweizerische Multiple Sklerose Gesellschaft/Société suisse de la Sclérose en plaques, Scleroseforeningen, Stichting MS Research. 34 Pediatric MS and other demyelinating disorders in childhood: Current understanding, diagnosis and management The understanding of multiple sclerosis (MS) and other demyelinating disorders in childhood has advanced considerably in the last ten years. This publication accompanies a series of articles written by subject experts that highlight the advances, unanswered questions and new challenges in understanding, diagnosis and management. It provides a short summary of the key points from each article, and a list of resources and further reading where you can find links to the full articles, all of which are available open access (free).